#JPM23: Fire­side chat with Bar­ry Greene: 'There's no straight line to suc­cess'

End­points News founder John Car­roll sat down dur­ing JP Mor­gan with Sage CEO Bar­ry Greene to talk about all things neu­ro. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

John Car­roll:

Bar­ry Greene, the CEO of Sage Ther­a­peu­tics, who af­ter a 17-year run at Al­ny­lam jumped and end­ed up as CEO of a com­pa­ny that’s now look­ing to field its first drug. And I want­ed to talk to you a lit­tle bit about, first of all, what mo­ti­vates you and what mo­ti­vat­ed you to do what you did here in go­ing over to a dif­fer­ent com­pa­ny at that stage in your ca­reer? What was go­ing on? What was the dri­ving fac­tor that got you over to Sage?

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN